CTI Honored with 2017 Thoroughbred Award

CTI was recognized along with 17 other companies that located, expanded or were launched in the region in 2016. CTI announced back in August 2016 that they would be relocating their corporate headquarters to Covington, Kentucky by mid-2017.

Galectin Therapeutics and CTI Announce Positive New Psoriasis and Atopic Dermatitis Clinical Data

“We are very pleased to continue our collaboration with Galectin through this exciting trial that is showing promise for patients with severe skin diseases,” according to Joseph McCafferty, Vice President Global Business Development at CTI. “Dr. Traber and his Galectin colleagues have been tremendous to work with and we are privileged to be a partner on several of their life-changing programs.”

Bexion and CTI Announce Collaboration on First-in-Human Trial for the Treatment of Cancer

"We are really enthused to be partnering with Bexion Pharmaceuticals,” according to Timothy Schroeder, CTI Founder and CEO. “They are an innovative organization with very strong regional ties – the drug was initially developed and licensed from Cincinnati Children’s Hospital Medical Center, early funding has predominantly come from the region, and the management and board have strong local connections. This program has the potential to be a game changer in the cancer arena.”

CTI Announces Site of New Global Headquarters

CTI will relocate its corporate headquarters from the Cincinnati suburb of Blue Ash, Ohio 17 miles south to Covington, Kentucky's RiverCenter complex, where it will initially occupy approximately 125,000 square feet. The relocation will help the company consolidate its locations and facilitate future growth.

"As we continue to expand the company presence in the Tri-state area, we hope to become a model for other companies, in growing our footprint throughout this incredibly rich region. It is a transformative time in the company's history, and we will look back positively on this decision and its impact on the company's ability to move life-changing therapies to patients around the world,” according to Timothy J. Schroeder, CTI Chief Executive Officer. 

CTI Announces Formation of Korean Subsidiary and Opening of Seoul Office

“The expansion into Korea is part of efforts to increase capacity for clinical research in one of Asia’s fastest-growing countries for drug development,” according to Patrick Earley, Vice President, International. “We have been working with leading Korean academic medical centers for a number of years, as well as collaborating with innovative Korean biotechnology companies. This expansion will only further enhance the relationships and collaborations we have in the country.”


Rare Disease / Orphan Disease

CTI is a leader in rare disease and orphan disease research with approximately 80% of our work falling into this category.

Learn More

Regenerative Medicine / Gene Therapy

Find out how CTI can provide value to regenerative medicine and gene therapy programs as a leader in the field.

Learn More

Phase I Studies

The CTI CRC Phase I unit is a state-of-the-art facility designed specifically to conduct early phase clinical pharmacology trials. Located on the campus of Mercy Hospital, this unit has access to a variety of clinical support services and emergency facilities.

Learn More

Participate in a Trial

Icon Careers Small Retina

CTI CRC is looking for volunteers to participate in our current trials. 

Learn More

Join our Team

Icon Briefcase Small Retina

CTI is always looking for talented individuals to join our team around the world!

Learn More